2021 Volume 57 Issue 1 Pages 162-166
Cervical cancer diagnosed during pregnancy occurs in approximately 1.4−4.6 in every 100,000 pregnancies. We report 2 cases that underwent neoadjuvant chemotherapy with carboplatin and paclitaxel（TC therapy） for cervical cancer during pregnancy.
Case 1 was a 40-year-old woman at 24 weeks gestation, who was diagnosed with stage IB1 squamous cell carcinoma of the cervix.
She was treated with 3 courses of TC therapy before Cesarean section at 34 weeks gestation to deliver a baby weighing 1,878 g.
Case 2 was a 34-year-old woman at 13 weeks gestation, who was diagnosed with stage IB1 squamous cell carcinoma of the cervix. She was treated with 5 courses of TC therapy before Cesarean section at 34 weeks gestation to deliver a baby weighing 1,944 g.
Both women underwent radical hysterectomy 3 weeks after their Cesarean sections, and they have had no recurrence for 5 years.
The baby born to Case 1 has shown normal growth and development until 3 years old, at the completion of follow-up. The baby born to Case 2 has shown delayed growth and bone development（approximately −1.9 standard deviation）at 5 years old.
Neoadjuvant chemotherapy during pregnancy remains controversial.
Neoadjuvant chemotherapy with TC therapy could be considered a safe and effective treatment option for cervical cancer during pregnancy. Especially, carboplatin has been reported to be less ototoxic than cisplatin. Neither baby developed hearing loss as a side effect of carboplatin.
